1. Home
  2. KITT vs CMMB Comparison

KITT vs CMMB Comparison

Compare KITT & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nauticus Robotics Inc.

KITT

Nauticus Robotics Inc.

HOLD

Current Price

$0.48

Market Cap

11.8M

Sector

Industrials

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$1.68

Market Cap

11.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KITT
CMMB
Founded
2014
2004
Country
United States
Israel
Employees
47
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
11.2M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
KITT
CMMB
Price
$0.48
$1.68
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
4.9M
45.6K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
101.67
EPS
N/A
0.04
Revenue
N/A
N/A
Revenue This Year
$2,936.06
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$42.00
Revenue Growth
N/A
N/A
52 Week Low
$0.46
$0.87
52 Week High
$6.93
$3.86

Technical Indicators

Market Signals
Indicator
KITT
CMMB
Relative Strength Index (RSI) 33.17 49.87
Support Level N/A $1.47
Resistance Level $1.02 $1.85
Average True Range (ATR) 0.05 0.16
MACD -0.00 -0.00
Stochastic Oscillator 9.65 38.71

Price Performance

Historical Comparison
KITT
CMMB

About KITT Nauticus Robotics Inc.

Nauticus Robotics Inc develops fully electric autonomous robotic solutions for subsea applications. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing related software to both the commercial and defense business sectors. The company's addressable markets include upstream, midstream, and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research, and subsea mining.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: